Published in final edited form as:

Cell Mol Life Sci. 2020 January ; 77(2): 351–363. doi:10.1007/s00018-019-03185-3.

Isorhapontigenin (ISO) Inhibits Stem Cell-like Properties and Invasion of Bladder Cancer Cell by Attenuating CD44 Expression

Yisi Luo[#], Zhongxian Tian[#], Xiaohui Hua, Maowen Huang, Jiheng Xu, Jingxia Li, Haishan Huang, Mitchell Cohen, Chuanshu Huang^{*}

Nelson Institute and Department of Environmental Medicine, New York University School of Medicine, 341 East 25th Street, New York, NY 10100, USA

Abstract

Cancer stem cells (CSC) is highly associated with poor prognosis in cancer patients. Our previous studies report that isorhapontigenin (ISO) downregulates SOX2-mediated cyclin D1 induction and stem-like cell properties in glioma stem-like cells. The present study revealed that ISO could inhibit stem cell-like phenotypes and invasivity of human bladder cancer (BC) by specific attenuation of expression of CD44 but not SOX-2, at both the protein transcription and degradation levels. On the one hand, ISO inhibited *cd44* mRNA expression through decreases in Sp1 direct binding to its promoter region binding site, resulting in attenuation of its transcription. On the other hand, ISO also downregulated USP28 expression, which in turn reduced CD44 protein stability. Further studies showed that ISO treatment induced miR-4295, which specific bound to 3'-UTR activity of *USP28* mRNA and inhibited its translation and expression, while miR-4295 induction was mediated by increased Dicer protein to enhance miR-4295 maturation upon ISO treatment. Our results provide the first evidence that ISO has a profound inhibitory effect on human BC stem cell-like phenotypes and invasivity through the mechanisms distinct from those previously noted in glioma stem-like cells.

Keywords

Isorhapontigenin; bladder cancer; stem cell-like properties; CD44; USP28

1. Introduction

Bladder cancer (BC) originates from the urothelial epithelium and at least 50% of patients with muscle-invasive bladder cancer (MIBC) die from metastases within 2 years, and the 5-year survival rate for metastatic BC is only 6% [1]. In 2019, about 80,470 new cases of BC will have been diagnosed in the US [2]. Although the mortality rate from bladder cancer is

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <https://www.springer.com/aam-terms-v1>

^{*}**Corresponding author:** Chuanshu Huang, MD/PhD, Department of Environmental Medicine, New York University School of Medicine, 341 East 25th St., New York, New York 10010; Tel: 646-754-9457; Fax: 646-754-9471; Chuanshu.huang@nyulangone.org.
[#]These authors contributed equally to this work.

Publisher's Disclaimer: This Author Accepted Manuscript is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

not as high as that of lung and breast cancer, its high recurrence rate is an urgent problem that needs to be addressed. Based on clinic pathology, BC is mainly divided into two phenotypes, muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). Approximately 90% patients with NMIBC are treated by surgery alone or in combination with other treatments; however, about 50%–70% of patients will have a recurrence and 5–20% of relapsed patients even will progress to MIBC. Compared with NMIBC, patients with MIBC have a higher risk of mortality [3–5]. Increasing evidence has proven that stem cell-like cancer cells (CSC), which have some traits of normal stem cells including self-renewal ability, play a significant role in tumor recurrence and metastasis and drug-resistance [5–7]. For these reasons, evaluating potential therapeutic approaches, for example, finding new special compounds for CSC-targeted cancer therapies, is of extreme importance for improving the clinical outcomes of BC patients. Along these lines, a natural saponin ginsenoside-Rb1 has already been shown to effectively suppress ovarian cancer CSC self-renewal without regrowth [8].

Isorhapontigenin (ISO), a highly functionalized derivative stilbene, was original isolated from the Chinese herb *Gnetum cleistostachyum* [9,10] and is now commercially available. Our earlier *in vitro* and *in vivo* studies demonstrated that ISO possesses a lot of anti-cancer activities. Those studies showed that ISO treatment of T24T human-invasive BC cells induced apoptosis through down-regulation of the anti-apoptotic protein XIAP [10]. Recently, our studies also found that ISO inhibited cell invasion in both UMUC3 and T24T cells through a targeting of the STAT1-FOXO1-MMP2 axis [11]. Moreover, our work showed that ISO exhibited clear inhibitory effects on BC cell growth that was mediated by the miR-137/Sp1/cyclin D1 pathway, both *in vitro* and *in vivo* [12]. These results provided substantial support for defining ISO as a promising therapeutic natural compound worthy of further exploration of its potentially powerful anti-cancer utility. Even so, to date, nothing is known about if ISO can inhibit bladder stem cell-like cancer cells. Thus, in the current studies reported here, inhibitory effects of ISO on human BC cell sphere formation properties and potential underlying molecular mechanisms for these effects were investigated.

CD44, an important surface receptor for hyaluronate, has been identified as a major cancer stem cell marker for certain kinds of epithelial tumors, including bladder cancer [5,13]. CD44 possesses an extracellular, transmembrane, and intracellular domain [14,15] that contribute to inter-actions with various ligands. These interactions are essential for its many cellular functions, such as modulation of migration/invasion processes during cancer progression [16], angiogenesis [17], as well as bone metastasis [18]. Moreover, CD44, as a transcription factor, enables it to control cell signaling *via* binding to promoter response elements [19,20]. Indeed, data from the recent study found that knockdown of ATG7 accelerates CD44 protein degradation, which subsequently had an inhibitory effect on cell sphere formation and invasivity by human BC cells [21].

To our knowledge, the study reported here is the first to show that ISO inhibition of CD44 protein expression both at protein degradation and transcription level consequently impacted on BC cell stem-like properties and invasivity.

2. Materials and Methods

2.1 Plasmids, Antibodies, and Reagents

Short Palindromic Repeats (CRISPR)/Cas9 system specific targeting FOXO1 were bought from Applied Biological Materials (British Columbia, Canada). The plasmid containing luciferase reporter under control of a human CD44 gene promoter was constructed in a PGL3-BASIC vector using the primers (F) 5'-CCGCTCGAGACG TATGGGTGGATGAGAG-3' and (R) 5'-CCCAAGCTTATGAGGGCCTGAAGT. A CD44 promoter-driven luciferase reporter with a mutation in the SP1 binding site was constructed using a CD44 promoter-driven luciferase reporter with primers (F) 5'-CTCTTTCCACTTGGAG ATTACCA-3' and (R) 5'-TGGATATCCTGGGAGAGGAGCT-3'. A plasmid containing a luciferase reporter under control of human WT USP28 mRNA 3'UTR was constructed in a pMIR-report vector using primers (F) 5'-CCCAAGCTTACATAAG ATTCCGATCAGAC-3' and (R) 5'-CCGCTCGAGTTATTGCACATTTATAAAATCTG-3'. The primers for cloning the mutant of *usp28* mRNA 3'UTR luciferase reporter were (F) 5'-ATTGAAAATAAAATTCGTGTTTTTAGG TACAAA-3' and (R) 5'-TTTTGTACCTAAAACACGAATTTTATTTCAAT-3'. The miR-4295 inhibitor plasmid (HmiR-AN1540-AM02) was purchased from GeneCopoeia (Rockville, MD, USA).

Antibodies specific against human CD44 (#5640S), Oct4 (#2840S), Sox2 (#23064S), Nanog (#4903P), Skp1 (#2156), Skp2 (#4358), ITCH (#12117S), USP4 (#2651S), LC3A, LC3B (#4445S, autophagy kit), p62 (#88588), ELK1 (#9182), GAPDH (#5174), GFP (#2956S), FOXO1 (#9454S), STAT5 (#9363S), NFAT1 (#5861), Dicer (#5362S) were all purchased from Cell Signaling (Beverly, MA, USA). Antibodies specific for c-MYC (sc-40), Sp1 (sc-14027), E2F1 (sc-193), ACTB (sc-58673) and TUBA (sc-53646) were bought from Santa Cruz (Santa Cruz, CA, USA). Antibodies specific for FBW7 (QC43532-42348) was purchased from Aviva Systems Biology (San Diego, CA, USA). Antibodies specific for USP8 (#SAB1300068) was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). Alkaline phosphatase (AP)-conjugated secondary antibodies were purchased from Cell Signaling (Beverly, MA, USA).

Actinomycin D (ActD; sc-200906), CHX (sc-3508), MG132 (sc-201270), and bafilomycin (sc-201550) were purchased from Santa Cruz (Santa Cruz, CA, USA). The Dual Luciferase Assay kit was purchased from Promega (E1960). PolyJet™ DNA in Vitro Transfection Reagent was purchased from SignaGen Laboratories (SignaGen Laboratories, Gaithersburg, MD). TRIzol (#15596026) reagent and a Superscript™ First-Strand Synthesis system (#18080051) were bought from Invitrogen (Invitrogen, USA). Isorhapontigenin (ISO; purity > 99%) was purchased from Roche Pharma (New York, USA). ISO was dissolved in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich Corporation, USA, 67-68-5) to make a 20 mM stock solution; the same concentration of DMSO was used as a vehicle control in all experiments.

Culture medium DMEM mixture F-12 HAM was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA), penicillin, and streptomycin were bought from Corning (Manassas, USA). 0.5% Trypsin-EDTA (10 X) was purchased from Gibco (Maryland,

USA). Fetal bovine serum (FBS) was purchased from JRH Biosciences (Lenexa, Kansas, USA).

2.2 Western Blot Analysis

Western blotting was performed as previously reported [22,23]. In brief, cells were seeded into 6-well plates and cultured in normal FBS medium until a 70–80% confluence. The cells were then cultured in 0.1% FBS-containing medium for 12 hours, followed by treatment with different doses of ISO for the indicated times. Whole cell extracts were then prepared using cell lysis buffer, and proteins subsequently resolved by SDS-PAGE before electrotransfer to polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, USA). Each membrane was probed with a specific primary antibody that was ultimately detected by incubation of the membrane with the AP-secondary antibody and treatment with ECL Western blot substrate. All images of the stained membranes were acquired by scanning with a Typhoon FLA 7000 Phosphorimager (General Electric, Chicago, IL, USA).

2.3 Cell Culture and Transfection

The human BC cell line T24T was used as in previous studies [24,25]. These cells were cultured in DMEM/Ham's F-12 (1:1 volume) mixed medium containing 5% FBS, 1% penicillin/strepto-mycin, and 2 mM L-glutamine and maintained at 37°C in a 5% CO₂ incubator. All cell lines were subjected to DNA tests and authenticated before/after utilization for research by Genetica DNA Laboratories (PowerPlex 16 HS System). Stable transfections were performed using PolyJet™ DNA In Vitro Transfection Reagent according to manufacturer protocol. To isolate stable transfectants, cells were selected using G418, puromycin or hygromycin during incubation for 4–6 weeks; surviving cells after selection were pooled as stable mass transfectants as described previously [26,27].

2.4 RT-PCR and Quantitative Real-Time PCR

Total RNA was extracted using TRIzol as described in the instructions accompanying the miRNeasy Mini Kit (#217004) (Qiagen, Valencia, CA, USA). cDNA was synthesized with a SuperScript™ First-Strand Synthesis system. Analyses of mRNA expression was carried out using a Fast SYBR Green Master Mix Kit (#4385614) and a 7900HT Fast Real-Time PCR System (both Applied Biosystems, Pittsburgh, PA, USA). Data were analyzed as described previously [28]. The primers used were: *pre-miR4295* ([F] 5'-AATGGT-TTCCTTGCCTGTG-3'; [R] 5'-AGTCTAGTTTCTTAGCCTTG), human *USP28* ([F] 5'-AAA-ATTGTCGAAGTCATAC-3'; [R] 5'-GGATACTGGCCGAAGGTCTCA-3'), human *GAPDH* ([F] 5'-GACTCATGACCACAGTCCATGC-3'; [R] 5'-CAGGTCAGGTCCACCACTGA-3'), human *CD44* ([F] 5'-CACAATCCAGGCAACTCCTA-3'; [R] 5'-TACTCTGCTGCGTTGTCATT-3'); and human *Dicer* ([F] 5'-GAGTGTTTGAGGGATAG-3'; [R] 5'-CTGAGGTATGGGTTTGG-3').

2.5 Luciferase Reporter Assays

A miR-4295 promoter-driven luciferase reporter, CD44 promoter-driven luciferase reporter, *usp28* mRNA 3'UTR luciferase reporter, and pRL-TK, was each stably transfected into T24T cells. The stable transfectants were seeded into dedicated 96-well plates (10⁴/well) and

treated with ISO for the indicated time periods. The cells were then extracted with lysis buffer (25 mM Tris-phosphate [pH 7.8] 2 mmol/L EDTA, 1% Triton X-100, and 10% glycerol), and the luciferase activity in the extract was then evaluated in a MicroplateLuminometerLB96V microplate lumino-meter (Berthold GmbH & Co).

2.6 Chromatin Immunoprecipitation (ChIP) Assay

A ChIP assay was performed using an EZ CHIP kit (Millipore Technologies) according to manufacturer instructions. In brief, genomic DNA and total cell proteins were isolated as in a previous study [29]. Amplification of the region containing putative responsive elements of the human CD44 promoter was done using PCR and the primers (F) 5' - CTCTTTCCACTTGGGAAGATTCACCA-3' and (R) 5' -TGGATATCCTGGGA GAGGAGCT-3'. Resulting PCR products were separated over 2% agarose gels that were in turn stained with ethidium bromide. Final images were then generated using a standard UV light Alpha Innotech SP Image system (Alpha Innotech Corporation, San Leandro, CA, USA).

2.7 Sphere Formation Assay

To determine any impact of ISO on BC sphere formation, T24T cells were sorted from cultures by selection of sphere-formed cells. The isolated cells were then plated into 6-well ultra-low attachment culture plates (Corning, Kennebunk, ME, USA) and grown for 5–7 days as described in our previous studies [21]. The images were acquired using an Olympus DP71 microscope (Olympus 654 America Inc. Center Valley, PA, USA). At least six fields per well were counted. Data were expressed as relative sphere formation.

2.8 Actinomycin D Chase Experiment

Actinomycin D (ActD) chase experiments were used to test mRNA stability after ISO exposure. In brief, T24T cells were seeded into 6-well plates and cultured in 5% DMEM/ Ham's F-12 (1:1 volume) medium until 60–70% confluent. Thereafter, the cells were cultured in 0.1% FBS-containing medium for 12 hours, and subsequently treated with 20 μ M ISO or 0.1% DMSO in the presence or absence of 20 μ g/ml Act D for the indicated time periods. At the end of each period, total RNA was extracted and subjected to RT-PCR for evaluation of *miR-4295* expression.

2.9 Bioinformatic Analysis

The CD44 promoter region was analyzed for potential transcription factor binding sites using ALGGEN-PROMO Software. The *usp28* mRNA 3'UTR region was analyzed for potential miRNA binding sites by using TargetScanHuman 7.1 Software.

2.10 Statistical Analysis

All data were plotted as means $\pm$ SD of triplicate assays. A Student's t-test was employed to determine the significance of any differences between the various groups. A p-value < 0.05 was considered significant. All analyses were conducted using Prism 5.0 Software (GraphPad).

3. Results

3.1 Down-regulation of CD44 contributed to ISO inhibition of BC stem cell-like properties and invasivity

Prior studies noted that ISO could significantly inhibit mouse invasive BC development following BBN treatment *in vivo* and also inhibit BC cell invasivity *in vitro* [30]. Our recent work has also demonstrated that ATG7 promoted BC cell stem cell-like properties though an up-regulation in CD44s expression [21]. To explore whether ISO also impacted BC cell stem cell-like properties, sphere formation was assessed. The results (Fig. 1A & 1B) show that treatment of the T24T cells with ISO significantly reduced the numbers and sizes of tumorspheres that formed in a dose-dependent manner. To study how ISO influenced this property, Western blotting analyses of potential ISO downstream targets was performed. The data showed that ISO dramatically inhibited CD44 protein expression in a dose- and time-dependent manner in the T24T cells (Fig. 1C & 1D). In contrast, there was no consistent change observed in expression of other stem markers such as Oct4, Sox2, and Nanog.

To further test what role a CD44 protein inhibition might have, CD44 over-expression in T24T cells was first established and then the transfectants were treated with ISO to determine how ectopic expression of CD44 might regulate this cell stem cell-like property. It was found that ectopic expression of CD44 (Fig. 1E) remarkably increased sphere formation ability, and partially reversed the ISO suppression of sphere formation (Fig. 1F & S1) and invasion (Fig. 1G & 1H). Consistently, ISO also had partially inhibitory effect on over-expressed CD44 (Fig. 1E). Taken together, these results demonstrated that ISO inhibited BC stem cell-like properties and invasion though down-regulation of CD44 expression.

3.2 ISO attenuated CD44 protein stability by down-regulating USP28 in human BC cells

Because ISO treatment not only inhibited endogenous CD44 expression but also reduced ectopic CD44 protein expression in T24T cell, the study next examined if down-regulation of CD44 expression due to ISO was a result of changes in degradation of CD44 protein. In T24T cells treated with CHX alone or in combination with ISO for varying lengths of time, CD44 protein degradation rates were markedly increased in cells incubated with ISO + CHX as compared to in cells incubated with CHX alone (Fig. 2A). Based on this, it appeared that ISO exerted a down-regulating effect on CD44 protein expression *via* promotion of its degradation. Since protein degradation by either proteasomes or lysosomes plays an indispensable role in cells [31], the study next tested if autophagy could induce CD44 protein degradation. As seen in Figure S2A, there were no obvious differences in CD44 degradation rates between cells treated with ISO + BafA1 *vs.* those that received only ISO. On the other hand, MG132 could lead to accumulation of the CD44 protein (Fig. 2B), suggesting that ISO treatment regulated CD44 protein degradation *via* proteasomal degradation.

To further explore the above findings, the study here also examined proteins (such as ITCH, USPs, FBW7 etc.) that are associated with proteasomal-dependent protein degradation. Of these, USP28 protein expression was dramatically down regulated by ISO treatment (Fig. 2C), suggesting USP28 might be involved in the modulation of CD44 protein degradation.

To test this, a Flag-USP28 expression construct was transfected into T24T cells; as expected, USP28 over-expression led to increased CD44 protein expression (Fig. 2D). Further, ectopic expression of USP28 led to increased CD44 protein stability (Fig. 2E). Moreover, USP28 expression attenuated the ISO-induced inhibition of BC cell sphere formation (Fig. 2F & S2B). These outcomes were consistent with the findings of Zhu et. al. who reported that USP28 was a key de-ubiquitination enzyme that binds to CD44 protein and removes the ubiquitin group from CD44 protein, resulting in enhanced CD44 protein stability [21]. Taken together, these results showed that ISO promoted CD44 protein degradation *via* decreased USP28 protein expression.

3.3 ISO inhibited CD44 transcription specifically mediated by attenuating Sp1 in BC cells

Since the inhibition of ISO on endogenous CD44 was more than on exogenous ectopic expressed CD44, we anticipated that ISO might also have impact on *cd44* mRNA in BC cells. To test this notion, T24T cells were treated by ISO to determine effects on *cd44* mRNA expression. As shown in Fig. 3A, ISO treatment resulted in significant time-dependent decreases in the standard form of *cd44* (*cd44s*) mRNA. Using a luciferase reporter assay to determine CD44 promoter activity, it was seen here that ISO also inhibited CD44 promoter activity in a time-dependent manner (Fig. 3B). These results indicated ISO inhibited *cd44* mRNA at the transcriptional level.

To build on these findings, bioinformatics was used to analyze potential transcription factor binding sites in the CD44 promoter region. Though there are many potential transcription factors binding sites in the CD44 promoter region (including for FOXO1, Elk1, E2F1, c-MYC, NFAT1, Sp1, STAT5; Fig. S3A), to identify the specific transcription factor(s) participating in the modulation of CD44 transcription, related transcription factor protein abundance was determined after ISO treatment. As shown in Fig. 3C, treatment of T24T cells with ISO resulted in significant dose-dependent induction of FOXO1 and inhibition of c-MYC and Sp1 expression. There were no observable effects on expression of Elk1, E2F1, NFAT1, and STAT5. These results suggested that FOXO1, Sp1, and c-MYC were CD44 promoter transcription factor candidates. To test this, the effects of FOXO1 knockdown, c-MYC over-expression, and GFP-Sp1 ectopic expression on CD44 expression in T24T cells was next evaluated. As shown in Fig. S3B & S3C, FOXO1 knockout and c-MYC over-expression had no impact on CD44 expression. These results excluded both of FOXO1 and c-MYC in ISO inhibition of CD44 transcription. Western blotting confirmed the efficiency of Sp1 over-expression (Fig. 3D). Ectopic expression of GFP-Sp1 increased CD44 expression, and ISO treatment only a partially inhibition of ectopic expressed GFP-Sp1-induced CD44 expression (Fig. 3E). These results indicated that Sp1 is a key transcription factor mediating inhibition of CD44 transcription after ISO treatment. Consistent with GFP-Sp1 upregulation of CD44 expression, knock-down of Sp1 resulted in attenuation of CD44 expression (Fig. 3F). To verify if Sp1 is able to specific binding to the CD44 promoter, a point mutation in the Sp1 binding sites in a CD44 promoter luciferase reporter eliminated ISO-induced inhibition of CD44 promoter luciferase activity (Fig. 3G). Further, a chromatin immuno-precipitation (ChIP) assay - followed by PCR with primers specifically targeting the Sp1 binding region in the human CD44 promoter in T24T cells was carried out. As shown in Fig. 3H, Sp1 did directly bind to putative Sp1 binding sites in the CD44 promoter.

Lastly, to show the importance of Sp1 in the BC cell phenotype, cell sphere formation was again assayed. The results indicated that ectopic expression of GFP-Sp1 attenuated ISO inhibition of BC cell sphere formation (Fig. 3I & S3D). Further, knockdown of Sp1 inhibited BC cell sphere formation (Fig. 3J & S3E). Collectively, these findings revealed Sp1 played an important role in ISO-induced inhibition of CD44 transcription and protein expression in human BC cells, which in turn also impacted on cell phenotype/functionality.

3.4 ISO-induced miR4295 inhibited USP28 translation by affecting mRNA 3'-UTR activation

It was shown above that ISO inhibited USP28 expression that, in turn, weakened CD44 protein stability and ultimately led to inhibition of BC cell sphere formation. To clarify the mechanisms leading to the repressed USP28 protein expression, *usp28* mRNA expression was evaluated. The results indicated ISO treatment did not significant influence *usp28* mRNA expression (Fig. S4A), thereby precluding the possibility of effects at the transcriptional/post-transcriptional level. To ascertain if ISO affected USP28 protein stability in the T24T cells, cells treated with cycloheximide (CHX) or CHX + ISO were analyzed. The data indicated that USP28 protein expression was not overtly impacted (Fig. S4B), indicating protein degradation was not affected by ISO. As this suggested to us that ISO regulated USP28 expression at the translation level, and it is well-recognized that the 3'-UTR of a transcript can influence protein translation, *usp28* mRNA 3'-UTR luciferase reporters were therefore transfected into T24T cells and the cells were then treated with ISO. As shown in Fig. 4A, ISO treatment resulted in significant time-dependent reductions in *usp28* mRNA 3'-UTR activity, suggesting that ISO inhibited USP28 protein translation *via* regulation of *usp28* mRNA 3'-UTR activity.

Given that miRNAs are known to regulate mRNA 3'-UTR [32], a TargetScan software was employed to screen potential miRNA binding sites in the 3590–4840 bp region of the *usp28* mRNA 3'-UTR (Fig. S4C). To identify which of the nine miRNAs was responsible for regulation of USP28 protein translation, real-time PCR was used to assess expression of each miRNA in the T24T cells treated with ISO. The results showed that only miR-137 and miRNA-4295 were markedly induced by ISO treatment (in time-dependent manner), while miR-340-5P was slight affected and the other miRNA were unaffected (Fig. 4B). To identify whether miR-137 and/or miRNA-4295 acted as a regulator for inhibition of USP28 protein translation, miR-137 and miRNA-4295 were stably transfected into T24T cells (Fig. 4C & 4E). Over-expression of miRNA-4295 impaired USP28 and CD44 protein expression, while over-expression of miRNA-137 did not show any inhibitory effect on USP28 proteins expression but did partially inhibit expression of CD44 protein and Sp1 (Fig. 4D & 4F). This suggested that miR-4295, and not miR-137, played a major role in inhibition of USP28 translation.

Consistent with the inhibition of USP28 and CD44 by miR-4295, ectopic expression of miR-4295 was found to block USP28 3'-UTR luciferase reporter activity in a dual-luciferase reporter assay (Fig. 4G). To assess whether miR-4295 directly bound to the USP28 3'-UTR and then inhibited USP28 translation, a miR-4295-targeted site mutated USP28 3'-UTR luciferase reporter was constructed (Fig. S4D) and transfected into T24T cells. Upon

treatment with ISO, compared with outcomes in WT USP28 3'-UTR luciferase reporter-transfected cells, cells with a point mutation in the miR-4295 binding site in the USP28 3'-UTR-luciferase reporter displayed a loss of ISO inhibitory effects on USP28 3'UTR activity (Fig. 4H). Together, the data reveal how miR-4295 induced by ISO inhibited USP28 translation by binding directly to the *usp28* mRNA 3'-UTR region.

3.5 miR-4295 induction was crucial for ISO inhibitory effects on USP28 and CD44 expression, and BC sphere formation and invasivity

Both miR-4295 inhibitor plasmid and its vector were transfected into T24T cells; once the stable cell lines were established, miR-4295 expression level was evaluated. As expected, miR-4295 expression was decreased (Fig. 5A). In addition, this inhibition of miR-4295 expression not only increased USP28 3'-UTR activity but also promoted USP28 and CD44 protein expression (Fig. 5B & 5C). In order to determine if miR-4295 was involved in the effect of ISO on inhibiting cell sphere formation and cell invasivity, a cell sphere formation assay was also done. The results indicated that ISO inhibited this T24T(vector) cells stem cell-like property, and that this was reversed by the presence of the miR-4295 inhibitor (Fig. 5D & 5E). Inhibition of miR-4295 expression also blocked ISO inhibition of cell invasion by the BC cells (Fig. 5F & S5). These results revealed that miR-4295 induction is crucial for ISO inhibition of expression of USP28 and CD44, and BC sphere formation and invasion.

3.6 ISO promoted miR-4295 expression through up-regulation of Dicer protein expression

In the investigation of potential underlying mechanisms leading to increased miR-4295 expression, it was seen that ISO treatment only show a slight effect on miR-4295 promoter-driven luciferase activity (Fig. S6A). As a result, it is possible to exclude an ISO impact at the miR-4295 transcription level. To see whether ISO influenced miR-4295 expression *via* changes in miR4295 degradation, actinomycin D (ActD) was used to block new miRNA transcription in T24T cells treated with ISO or vehicle control (DMSO) and miR-4295 degradation kinetics was assessed. As shown in Fig. S6b, there was no significant difference in rates of miR-4295 degradation due to ISO treatment. As degradation was not overtly affected, this suggested that ISO might regulate miR-4295 maturation. To test this, pre-miR-4295 and miR-4295 expression in T24T cells treated with ISO for varying time periods was evaluated. As expected, miR-4295 expression was dramatically up-regulated by ISO; in contrast, pre-miR-4295 was down-regulated upon ISO treatment (Fig. 6A), suggesting that ISO promotes pre-miR4295 maturation. The ISO treatment also resulted in significant time-dependent up-regulation of Dicer protein expression in the cells (Fig. 6B). Given that Dicer is an important RNase III expressed in eukaryotes and is essential for miRNA maturation [33,34], these results revealed that ISO promoted miR-4295 maturation *via* up-regulation of Dicer.

To determine its functional role in the observed outcomes with ISO, analyses using knock-down of Dicer showed that this protein could reverse the inhibitory effects of ISO upon USP28, CD44 expression, and also blocked miR-4295 expression (Fig. 6C & 6D). Knocked-down of Dicer also attenuated ISO effects on expression of BC stem cell-like phenotypes (Fig. 6E & S6C). Collectively, these results demonstrated that ISO-induced Dicer expression could promote a miR-4295 maturation that subsequently inhibited USP28 translation by

targeting *usp28* mRNA 3'UTR and ultimately a decrease in CD44 protein stability as diagram in Fig. 6F.

4. Discussion

A presence of cancer stem cells (CSC) is closely associated with potential tumor metastasis and resistance to anti-cancer therapeutics [35,36]. As recurrence and drug resistance are two important characteristics of bladder cancer (BC) [37], it is urgent to find novel therapeutics to inhibit human BC stem-like cells. Given the results of our previous studies assessing the various biological effects of ISO both *in vitro* and *in vivo*, we believed that ISO could be a novel cancer therapeutic for BC patients. In the current study, we demonstrated that ISO imparted an inhibitory effect on expression of BC stem-like properties and invasivity, in part, by causing a downregulation of CD44 expression. It was also demonstrated that the down-regulation of CD44 by ISO was not only caused by an inhibition of the expression of/ interactions of deubiquitinating enzyme USP28 with CD44 leading to enhanced CD44 protein degradation but was also a result of a reduction in the expression/binding activity of transcription factor Sp1 that binds to CD44 promoter sites and resulted in inhibited CD44 transcription.

Accumulating evidence has demonstrated that CD44 expression is highly correlated to cancer stem cell phenotype, as well as overall tumor invasivity, metastatic potential, and chemo-resistance. CD44 has been shown to be a cancer stem cell marker in several cancers, including lung [38], breast [39], liver [40], bladder [5], and colorectal cancers [41]. Wu et al. reported that higher CD44 expression levels could increase spheroid colony formation by BC cells [42]. Our previous study also showed that CD44 is a crucial ATG7 downstream mediator critical for invasivity and metastatic potentials of human BC cells [21]. Thus, CD44 might be a potential target in for treatments of human high invasive BC.

The current novel findings of the ISO impact on BC stem cell-like properties indicates that these arose *via* distinctly different means from those through which ISO suppressed the growth of patient-derived glioblastoma spheres (i.e., via inhibition of SOX2 expression) [43]. The current study revealed that ISO both decreased Sp1-mediated *cd44* mRNA transcription and USP28 direct binding-mediated stabilization of CD44 protein. Further investigation of mechanisms underlying the relationship between CD44 expression and cancer stem cell phenotypes are essential.

Dicer is an RNase involved in biogenesis of microRNA (miRNA) as well as other small non-coding RNA (ncRNA) [44]. In recent years, studies have been performed to define factors regulating *Dicer* gene expression. Given the complexity of Dicer regulation, it is not surprising that a large amount of contradictory data has been generated. SOX4, a well-known transcription factor, positively-regulates Dicer transcription by directly binding to its promoter; in regards to cancer, this effect leads to subsequent suppression of melanoma cell invasivity [45]. It is of note that let-7 repressed Dicer expression by directly binding the dicer 3'-UTR region; this down-regulation leads to reduced expression of mature let-7, indicating a possible novel negative feedback loop existed [46]. Another report showed expression of human Dicer could be regulated by modification of phosphorylation or

SUMOylation [47,48]. The present study found that ISO treatment led to time-dependent increases in Dicer protein abundance, which, in turn, subsequently promoted miR-4295 maturation that resulted in down-regulation of USP28, acceleration of CD44 protein degradation, and ultimately brought about a significant reduction in stem-like properties of the human BC cells. Since precise regulation of Dicer expression is important in various physiological processes, future studies will analyze underlying mechanisms leading to Dicer accumulation due to ISO treatment.

Accumulating evidence has demonstrated that miR-4295, an essential miRNA, is involved in various biological processes. Over-expression miR-4295 is known to promote cell proliferation by a direct targeting of BTG1 in BC cells [49]. Our previous studies also found that miR-4295 could inhibit p63 α protein expression, an event that promoted malignant transformation of human bladder epithelial UROtsa cells [50]. Based on the literature, we anticipate that miR-4295 can act as an oncogenic miRNA in several cancers. On the other hand, by targeting deubiquitinating enzyme USP28, miR-4295 may also function as a tumor suppressor in BCs, may also in some cancer cells [51]. The current study showed that due to ISO treatment, increasing miR-4295 maturation though changes in Dicer expression, and increased direct binding of miR-4295 to *usp28* mRNA 3'UTR and inhibited USP28 protein translation, resulting in enhanced CD44 degradation. These changes, in turn, suppressed expression of BC stem-like properties. It is interesting that miR-4295 appears to display dual functions in BC cells in different phases of BC development. Of even greater note, according to Kaplan-Meier Plotter database analyses, miR-4295 expression is positive correlated with survival time of BC patients (see Supplementary Fig. S7A), which supports our hypothesis that induction of miR-4295 by ISO resulted in the inhibition of BC stem-like properties and invasion.

That ISO treatment impacted on USP28, a member of the ubiquitin-specific protease family that plays an important role in regulation of oncogene and tumor suppressor expression [52,53], represents an important finding. Deubiquitinating enzymes (DUB) have long been thought of as targets in many cancer treatments [54,55]. USP28 expression in BC is known to be positively associated with decreased survival of BC patients (Kaplan-Meier Plotter database; Supplementary Fig. S7B). This is consistent with several studies reporting that USP28 over-expression was involved in the progression of certain cancers, including gliomas [56] and BC [57]. The current study found that ISO inhibited USP28 expression, thereby promoting CD44 protein degradation and suppressing human BC sphere formation. Consistently, our previous study found that ATG7 regulates CD44 protein expression through USP28 binding to CD44 and promotes the deubiquitination of CD44, consequently, increasing its protein stabilization [21]. Importantly, we further demonstrated here that USP28 could binding CD44 by immunoprecipitation [21]. Based on our results here, we identify that USP28, a ubiquitin-specific protease, plays a significant role in inhibition of human BC stem-like properties by ISO treatment.

In summary, the current study showed that ISO imparted critical inhibitory effects on human BC cell stem-like properties through down-regulation of expression of the well-known stem marker CD44. Mechanistically, on one hand, ISO-induced reduction of CD44 expression appeared to be mediated by inhibition of transcription factor Sp1 expression. On the other

hand, Dicer induction by ISO promoted miR-4295 maturation, which in turn inhibited USP28 protein translation by targeting its 3'UTR region and then led to a subsequent speeding up of CD44 protein degradation. These findings not only revealed that ISO could impart inhibitory effects on human BC cell stem-like properties, but also provided a basis for the possible clinical use of ISO as a novel mechanism-based cancer therapeutic against human bladder cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Grant support: This work was partially supported by grants from NIH/NCI CA177665, CA217923, CA229234, CA165980, and NIH/NIEHS ES000260.

Abbreviations

ActD	Actinomycin D
AP	alkaline phosphatase
BAF	Bafilomycin A1
BC	bladder cancer
ChIP	Chromatin Immunoprecipitation
CHX	cycloheximide
CSC	cancer stem cells
DMSO	Dimethyl sulfoxide
DUB	Deubiquitinating enzymes
FBS	Fetal bovine serum
IgG	immuno-globulin G
ISO	Isorhapontigenin
MIBC	muscle-invasive bladder cancer
miR-4295	Hsa-microRNA-4295
ncRNA	non-coding RNA
NMIBC	non-muscle-invasive bladder cancer
RT-PCR	reverse transcription-polymerase chain reaction
WT	wide type

3'UTR

3'-Untranslated Regions

6. References

- [1]. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, et al. (2014). Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer (Review). *Nat Rev Urol*, 11(7), 400–410. doi: 10.1038/nrurol.2014.129. [PubMed: 24960601]
- [2]. cancer-facts-and-figures-2019 (2019). *CA Cancer J Clin*, 69(1):7–34. doi:doi: 10.3322/caac.21551. [PubMed: 30620402]
- [3]. Magee JA, Piskounova E, & Morrison SJ (2012). Cancer stem cells: impact, heterogeneity, and uncertainty. *Cancer cell*, 21(3), 283–296. [PubMed: 22439924]
- [4]. Khandelwal P, Abraham SN, & Apodaca G (2009). Cell biology and physiology of the uroepithelium. *American Journal of Physiology-Renal Physiology*, 297(6), F1477–F1501. [PubMed: 19587142]
- [5]. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. (2009). Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. *Proceedings of the National Academy of Sciences*, 106(33), 14016–14021.
- [6]. Britton KM, Kirby JA, Lennard TW, & Meeson AP (2011). Cancer stem cells and side population cells in breast cancer and metastasis. *Cancers*, 3(2), 2106–2130. [PubMed: 24212798]
- [7]. Dou J, & Gu N (2010). Emerging strategies for the identification and targeting of cancer stem cells. *Tumor Biology*, 31(4), 243–253. [PubMed: 20336402]
- [8]. Deng S, Wong CKC, Lai H-C, & Wong AST (2017). Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/ β -catenin signaling and epithelial-to-mesenchymal transition. *Oncotarget*, 8(16), 25897. [PubMed: 27825116]
- [9]. Huang K-S, Wang Y-H, Li R-L, & Lin M (2000). Stilbene dimers from the lianas of *Gnetum hainanense*. *Phytochemistry*, 54(8), 875–881. [PubMed: 11014282]
- [10]. Fang Y, Yu Y, Hou Q, Zheng X, Zhang M, Zhang D, et al. (2012). The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP. *The Journal of biological chemistry*, 287(42), 35234–35243. doi: 10.1074/jbc.M112.389494. [PubMed: 22896709]
- [11]. Jiang G, Wu AD, Huang C, Gu J, Zhang L, Huang H, et al. (2016). Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis. *Cancer Prevention Research*, canprevres.0338.2015. doi: 10.1158/1940-6207.capr-15-0338.
- [12]. Zeng X, Xu Z, Gu J, Huang H, Gao G, Zhang X, et al. (2016). Induction of miR-137 by isorhapontigenin (ISO) directly targets Sp1 protein translation and mediates its anticancer activity both in vitro and in vivo. *Molecular cancer therapeutics*.
- [13]. Kimura Y, Goi T, Nakazawa T, Hirono Y, Katayama K, Urano T, et al. (2013). CD44variant exon 9 plays an important role in colon cancer initiating cells. *Oncotarget*, 4(5), 785. [PubMed: 23800986]
- [14]. Culty M, Nguyen HA, & Underhill CB (1992). The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. *The Journal of cell biology*, 116(4), 1055–1062. [PubMed: 1370836]
- [15]. Iczkowski KA (2010). Cell adhesion molecule CD44: its functional roles in prostate cancer. *Am J TranslRes*, 3(1), 1–7.
- [16]. Lokeshwar B, Lokeshwar V, & Block N (1995). Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. *Anticancer research*, 15(4), 1191–1198. [PubMed: 7544562]
- [17]. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, & DeLisser HM (2001). Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. *Journal of Biological Chemistry*, 276(39), 36770–36778. [PubMed: 11448954]

- [18]. McFarlane S, Coulter JA, Tibbits P, O'Grady A, McFarlane C, Montgomery N, et al. (2015). CD44 increases the efficiency of distant metastasis of breast cancer. *Oncotarget*, 6(13), 11465. [PubMed: 25888636]
- [19]. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, et al. (2001). Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. *J Cell Biol*, 155(5), 755–762. [PubMed: 11714729]
- [20]. Thorne RF, Legg JW, & Isacke CM (2004). The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. *Journal of cell science*, 117(3), 373–380. [PubMed: 14702383]
- [21]. Zhu J, Huang G, Hua X, Li Y, Yan H, Che X, et al. (2019). CD44s is a crucial ATG7 downstream regulator for stem-like property, invasion, and lung metastasis of human bladder cancer (BC) cells. *Oncogene*. doi:10.1038/s41388-018-0664-7.
- [22]. Ding J, Li J, Xue C, Wu K, Ouyang W, Zhang D, et al. (2006). Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. *Journal of Biological Chemistry*, 281(34), 24405–24413. [PubMed: 16809336]
- [23]. Zhang D, Li J, Zhang M, Gao G, Zuo Z, Yu Y, et al. (2012). The Requirement of c-Jun N-terminal kinase2 in Regulation of hypoxia inducing factor-1 α mRNA Stability. *Journal of Biological Chemistry*, jbc. M112. 365882.
- [24]. Jin H, Yu Y, Hu Y, Lu C, Li J, Gu J, et al. (2015). Divergent behaviors and underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T bladder cancer cell lines. *Oncotarget*, 6(1), 522. [PubMed: 25402510]
- [25]. Gildea JJ, Golden WL, Harding MA, & Theodorescu D (2000). Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. *Genes, Chromosomes and Cancer*, 27(3), 252–263. [PubMed: 10679914]
- [26]. Song L, Li J, Zhang D, Liu Z. g., Ye J, Zhan Q, et al. (2006). IKK β programs to turn on the GADD45 α -MKK4-JNK apoptotic cascade specifically via p50 NF- κ B in arsenite response. *The Journal of Cell Biology*, 175(4), 607–617. doi:10.1083/jcb.200602149. [PubMed: 17116751]
- [27]. Song L, Li J, Ye J, Yu G, Ding J, Zhang D, et al. (2007). p85 α acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation. *Molecular and cellular biology*, 27(7), 2713–2731. [PubMed: 17242187]
- [28]. Huang C, Zeng X, Jiang G, Liao X, Liu C, Li J, et al. (2017). XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell. *Journal of hematology & oncology*, 10(1), 6. [PubMed: 28057023]
- [29]. Song L, Gao M, Dong W, Hu M, Li J, Shi X, et al. (2011). p85 α mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response. *Oncogene*, 30(11), 1360. [PubMed: 21057544]
- [30]. Jiang G, Wu AD, Huang C, Gu J, Zhang L, Huang H, et al. (2016). Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis. *Cancer Prevention Research*, canprevres.0338.2015.
- [31]. Wang X, & Robbins J (2014). Proteasomal and lysosomal protein degradation and heart disease. *Journal of molecular and cellular cardiology*, 71, 16–24. [PubMed: 24239609]
- [32]. Kim DH, Sntrom P, Snove O, & Rossi JJ (2008). MicroRNA-directed transcriptional gene silencing in mammalian cells. *Proceedings of the National Academy of Sciences*.
- [33]. Winter J, Jung S, Keller S, Gregory RI, & Diederichs S (2009). Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nature cell biology*, 11(3), 228. [PubMed: 19255566]
- [34]. Ha M, & Kim VN (2014). Regulation of microRNA biogenesis (Review Article). *Nature Reviews Molecular Cell Biology*, 15, 509. doi:10.1038/nrm3838. [PubMed: 25027649]
- [35]. Enderling H, Hlatky L, & Hahnfeldt P (2013). Cancer Stem Cells: A Minor Cancer Subpopulation that Redefines Global Cancer Features. *Frontiers in Oncology*, 3, 76. doi:10.3389/fonc.2013.00076. [PubMed: 23596563]

- [36]. Kondo T (2007). Stem cell-like cancer cells in cancer cell lines. *Cancer Biomarkers*, 3(4–5), 245–250. [PubMed: 17917153]
- [37]. Ohishi T, Koga F, & Migita T (2015). Bladder cancer stem-like cells: their origin and therapeutic perspectives. *International journal of molecular sciences*, 17(1), 43.
- [38]. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. (2013). Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. *PloS one*, 8(3), e57020–e57020. doi:10.1371/journal.pone.0057020. [PubMed: 23469181]
- [39]. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, & Clarke MF (2003). Prospective identification of tumorigenic breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, 100(7), 3983–3988. doi:10.1073/pnas.0530291100. [PubMed: 12629218]
- [40]. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. (2008). Significance of CD90+ cancer stem cells in human liver cancer. *Cancer cell*, 13(2), 153–166. [PubMed: 18242515]
- [41]. Dalerba P, Dylla SJ, Park I-K, Liu R, Wang X, Cho RW, et al. (2007). Phenotypic characterization of human colorectal cancer stem cells. *Proceedings of the National Academy of Sciences*, 104(24), 10158–10163.
- [42]. Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, et al. (2013). Silibinin inhibits β -catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. *Cellular signalling*, 25(12), 2625–2633. [PubMed: 24012496]
- [43]. Xu Z, Zeng X, Xu J, Xu D, Li J, Jin H, et al. (2015). Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis. *Neuro-oncology*, 18(6), 830–839. [PubMed: 26681767]
- [44]. Hannon GJ (2002). RNA interference. *nature*, 418(6894), 244. [PubMed: 12110901]
- [45]. Jafarnejad SM, Ardekani GS, Ghaffari M, Martinka M, & Li G (2013). Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion. *Oncogene*, 32(17), 2131. [PubMed: 22689055]
- [46]. Tokumaru S, Suzuki M, Yamada H, Nagino M, & Takahashi T (2008). let-7 regulates Dicer expression and constitutes a negative feedback loop. *Carcinogenesis*, 29(11), 2073–2077. [PubMed: 18700235]
- [47]. Rigbolt KT, Prokhorova TA, Akimov V, Henningsen J, Johansen PT, Kratchmarova I, et al. (2011). System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. *Sci. Signal*, 4(164), rs3–rs3. [PubMed: 21406692]
- [48]. Gross TJ, Powers LS, Boudreau RL, Brink B, Reisseter A, Goel K, et al. (2014). A microRNA processing defect in smokers' macrophages is linked to SUMOylation of the endonuclease DICER. *The Journal of biological chemistry*, 289(18), 12823–12834. doi:10.1074/jbc.M114.565473. [PubMed: 24668803]
- [49]. Nan Y-H, Wang J, Wang Y, Sun P-H, Han Y-P, Fan L, et al. (2016). MiR-4295 promotes cell growth in bladder cancer by targeting BTG1. *American journal of translational research*, 8(11), 4892. [PubMed: 27904689]
- [50]. Jin H, Xu J, Guo X, Huang H, Li J, Peng M, et al. (2016). XIAP RING domain mediates miR-4295 expression and subsequently inhibiting p63 α protein translation and promoting transformation of bladder epithelial cells. *Oncotarget*, 7(35), 56540. [PubMed: 27447744]
- [51]. Zhang L, Xu B, Qiang Y, Huang H, Wang C, Li D, et al. (2015). Overexpression of deubiquitinating enzyme USP 28 promoted non-small cell lung cancer growth. *Journal of cellular and molecular medicine*, 19(4), 799–805. [PubMed: 25656529]
- [52]. Zhen Y, Knobel PA, Stracker TH, & Reverter D (2014). Regulation of USP28 de-ubiquitinating activity by SUMO conjugation. *Journal of Biological Chemistry*, jbc. M114. 601849.
- [53]. Valero R, Bayes M, Francisca Sanchez-Font M, Gonzalez-Angulo O, Gonzalez-Duarte R, & Marfany G (2001). Characterization of alternatively spliced products and tissue-specific isoforms of USP28 and USP25. *Genome Biology*, 2(10), research0043.1. doi:10.1186/gb-2001-2-10-research0043.
- [54]. Lim K-H, & Baek K-H (2013). Deubiquitinating enzymes as therapeutic targets in cancer. *Current pharmaceutical design*, 19(22), 4039–4052. [PubMed: 23181570]

- [55]. Nicholson B, Marblestone JG, Butt TR, & Mattern MR (2007). Deubiquitinating enzymes as novel anticancer targets. *Future oncology* (London, England), 3(2), 191–199. doi: 10.2217/14796694.3.2.191.
- [56]. Wang Z, Song Q, Xue J, Zhao Y, & Qin S (2016). Ubiquitin-specific protease 28 is overexpressed in human glioblastomas and contributes to glioma tumorigenicity by regulating MYC expression. *Experimental Biology and Medicine*, 241(3), 255–264. [PubMed: 26209720]
- [57]. Guo G, Xu Y, Gong M, Cao Y, & An R (2014). USP28 is a potential prognostic marker for bladder cancer. *Tumor Biology*, 35(5), 4017–4022. [PubMed: 24347490]

Fig 1. ISO inhibition of BC stem-like properties through inhibiting CD44 that was also important for changes in invasivity.

(A & B) T24T cells were treated with ISO at indicated concentrations for 7 days to determine impact on sphere formation ability. The number of spheroid-forming cells in each image was counted as described in Methods. Bars shown are means $\pm$ SD from three independent experiments. *Significant difference relative to controls ($p < 0.05$). (C & D) T24T cells were treated with ISO at indicated concentrations or for indicated times, and then evaluated for stemness marker protein expression using Western blots. (E) Over-expression of CD44 constructs were stably transfected into T24T cells; the transfectants were then treated with 20 μ M ISO for 12 hours, and then underwent Western Blot analyses to determine CD44 expression levels. (F) Over-expression of CD44 could not reverse ISO inhibition of sphere formation. *Significant difference between indicated cells treated with or without 20 μ M ISO ($p < 0.05$). (G & H) Invasivity of T24T (vector) and T24T (CD44) cells treated with or without 20 μ M ISO for 24 hours was evaluated using a BD BioCoat™ Matrigel™ Invasion Chamber. After incubation for 24 hours, cells were fixed and stained as described in Methods. *Significant difference ($p < 0.05$).

Fig 2. ISO proceeding CD44 degradation through attenuating USP28 expression.

(A) Cycloheximide (CHX) (50 μ M) in combination with/without ISO (20 μ M) was added into the medium and the cells were incubated for the indicated times. Cells were then extracted for determination of CD44 protein expression using Western blots. (B) CD44 protein accumulation due to MG132 (10 μ M). (C) T24T cells were treated with 20 μ M ISO for the indicated times, then extracted; extracts were subjected to Western blot analyses to determine the protein expressions indicated. (D) T24T cells were transfected with Flag-USP28 expression vector or control vector, thereafter, the transfectants were extracted and subjected to Western blot to determine the protein expressions indicated. (E) T24T (vector) and T24T (Flag-USP28) cells were pre-treated with or without MG132 in the presence or absence of CHX for the indicated time periods before cell extracts were prepared and analyzed by Western blot for determination of CD44 status. (F) Cell sphere formation abilities of T24T (vector) and T24T (Flag-USP28) cells treated with or without 20 μ M ISO were determined. *Significant difference ($p < 0.05$).

Fig 3. Sp1 down-regulation mediated ISO inhibition of CD44 transcription.

(A) Total RNA isolated from T24T cells treated with 20 μ M ISO for indicated time periods was subjected to RT-PCR to determine *cd44* mRNA expression. (B) Both CD44 luciferase reporter and pRL-TK were co-transfected into T24T cells, and the transfectants were treated with 20 μ M ISO for indicated times. Luciferase activity was evaluated as described in Methods. *Significant difference ($p < 0.05$). (C) Indicated transcription factors in T24T cells were determined by Western Blot after cells were treated with 20 μ M ISO for indicated times. (D) GFP-Sp1 plasmid or vector was transfected into T24T cells, the transfectants were extracted and subjected to Western blot to determine the protein expressions indicated. (E & F) Sp1 was responsible for ISO inhibition of CD44 transcription. (G) T24T cells were stably transfected with CD44 promoter-driven luciferase or the Sp1-binding site mutant, and the stable transfectants were treated with 20 μ M ISO. Luciferase activity was evaluated as described in Methods. (H) ChIP assay was carried out with anti-GFP antibody. DNA was extracted from GFP agarose or control IgG. Total sonicated nuclei were used as Input input control. Specific Sp1 binding DNA regions of the CD44 promoter were then amplified by PCR. PCR products were separated over 2% agarose gels that were then stained with ethidium bromide and examined under UV light. (I) T24T (vector) and T24T (GFP-Sp1) cells were treated with/without ISO (20 μ M) to determine sphere formation ability. *Significant difference ($p < 0.05$). (J) T24T (nonsense) and T24T (shSp1) cells were used in sphere formation assay as described in Methods. *Significant difference ($p < 0.05$).

Fig 4. Induction of miR-4295 by ISO, which bound to USP28 3'UTR and inhibited USP28 protein translation in human BC cells.

(A) USP28 3'-UTR luciferase reporters were co-transfected with pRL-TK into T24T cells; stable transfectants were exposed to 20 μ M ISO for the indicated time periods to assess the ISO inhibition of USP28 3'UTR luciferase activity. *Significant difference ($p < 0.05$). (B) Expression levels of predicted miRNA were evaluated using quantitative real-time PCR. T24T cells were treated with medium containing either vehicle or 20 μ M ISO. (C & E) Over-expression of miR-137 and miR-4295 in T24T cells. *Significant difference ($p < 0.05$). (D & F) miR-4295, but not miR-137, inhibited USP28 and CD44 protein expression. (G) Inhibition of USP28 3'UTR activity by ectopic expression of miR-4295 in T24T cells. *Significant difference ($p < 0.05$). (H) miR-4295 binding site was crucial for ISO inhibition of USP28 3'UTR luciferase activity. *Significant difference ($p < 0.05$).

Fig 5. miR-4295 inhibitor reversed ISO inhibition of USP28 and CD44 expression, USP28 3'UTR activity, and cell sphere formation, as well as cell invasion in human BC cells.

(A) miR-4295 inhibitor constructs were stably transfected into T24T cells. The inhibition efficiency of miR-4295 was assessed by quantitative real-time PCR. *Significant difference ($p < 0.05$). (B & C) miR-4295 inhibitor could not block USP28 3'UTR luciferase activity and inhibit USP28 and CD44 expression (assessed via Western blot). (D & E) miR-4295 inhibitor reversed ISO inhibition of cell sphere formation. *Significant difference in comparison to vehicle control ($p < 0.05$). (F) miR-4295 inhibitor also reversed ISO inhibition of cell invasion. *Significant difference in comparison to vehicle control ($p < 0.05$).

Fig 6. ISO accelerated miR-4295 maturation by Dicer.

(A) miR-4295 and pre-miR-4295 assessed (via qRT-PCR) in T24T cells treated with 20 μ M ISO for the time periods indicated. *Significant difference ($p < 0.05$). (B) Dicer expression induced by ISO (20 μ M) was evaluated using Western blot. (C) T24T (vector) and T24T (shDicer) cells were treated with 20 μ M ISO for the time periods indicated, and the presence of indicated proteins evaluated using Western blot. (D) Knockdown Dicer reduced miR-4295 expression using qRT-PCR. *Significant difference in comparison to vector ($p < 0.05$). (E) Cell sphere formation by cells transfected with shDicer or nonsense vector. Transfectants were exposed to 20 μ M ISO for 7 d before analyses using microscopy. *Significant difference between indicated transfectants and between vehicle- and ISO-treated groups ($p < 0.05$). (F) The schematic summary of molecular mechanisms underlying inhibition of human bladder cancer stem cell-like phenotypes and invasivity upon ISO treatment.